Rifampicin Resistant Tuberculosis in a Secondary Health Institution in Nigeria, West Africa
|Shittu O Rasaki1*, Akanbi II A AJibola2, Sanni A Musa3, Alabi K Moradeyo4, Odeigah LO4, Sule G Abdullateef5, Wale Adeoti6 and Isiaka-Lawal Salamat7|
|1Department of Family Medicine, Kwara State Specialist Hospital, Sobi, Kwara State, Nigeria|
|2Department of Microbiology, University of Ilorin Teaching Hospital, Kwara State, Nigeria|
|3Department of Haematology, Kwara State Specialist Hospital, Sobi, Ilorin, Nigeria|
|4Department of Family Medicine, University of Ilorin Teaching Hospital, Kwara State, Nigeria|
|5Department of Family Medicine, Ahmadu Bello University, Teaching Hospital, Zaria, Nigeria|
|6Chest clinic, Kwara State Specialist Hospital, Sobi, Ilorin, Kwara State, Nigeria|
|7Department of obstetrics and gynaecology, Kwara State Specialist Hospital, Sobi, Ilorin, Nigeria|
|Corresponding Author :||Shittu RO
Head of Department of Family Medicine
Kwara State Specialist Hospital
Sobi, Ilorin, Kwara State, Nigeria
E-mail: [email protected]
|Received March 17, 2014; Accepted April 22, 2014; Published April 26, 2014|
|Citation: Rasaki SO, AJibola AA, Musa SA, Moradeyo AK, LO O, et al. (2014) Rifampicin Resistant Tuberculosis in a Secondary Health Institution in Nigeria, West Africa. J Infect Dis Ther 2:139. doi: 10.4172/2332-0877.1000139|
|Copyright: © 2014 Rasaki SO, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.|
|Related article at
Pubmed Scholar Google
Background: Rifampicin-dependent tuberculosis is an unrecognized and potentially serious treatment issue. Rifampicin resistance is a risk factor for poor outcome in tuberculosis. It is prevalent in Nigeria. Therefore, we sought to examine the pattern of rifampicin resistance tuberculosis in Nigeria, West Africa.
Method: One hundred and forty tuberculosis cases were referred to the chest clinic of Sobi Specialist Hospital from January to December 2013. Sputum samples were obtained from them, smeared on glass slides, stained using Ziehl Neelsen Stain and later observed under light microscopy. The GeneXpert MTB/RIF assay was used to simultaneously detect TB and rifampicin resistance.
Result: The minimum age of the patients was 18years, while the maximum was 83. The mean age was 38.39± 13.75. There was male preponderance 84(60%), compared to 56(40%) female. The secondary health institution made the highest referral. Forty eight (34.3%) had smear-positive TB, while 92(65.7%) were sputum negative. Thirty two (38.1%) male out of 84 and 12(21.4%) female out of 56 were sensitive to Rifampicin, while 6(7.1) male out of 84 and 4 (7.1%) female out of 56 were resistant to it. Forty four (31.4%) were MD-TB positive with a prevalence of 31.4%. Ten (7.2%) were Rifampicin resistant; this included 6 males and females. This was statically significant.
Conclusion: Our study highlights that physicians should have high index of suspicion for rifampicin resistant tuberculosis in patients refractory to anti-TB treatment. The MTB/RIF test is a useful method for rapid diagnosis of TB and detection of RIF-resistance strains. There is need for increasing effort to interrupt the transmission of RIF-TB.